Pricing Log in Create free account
Saturday 31 October 2026 Export JNJ’s income statement to Excel — free account

Johnson & Johnson

JNJ Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.

273.71 1.49 −0.54%
Market cap
$662.5B
P/E
31.7×
Fwd P/E
38.6×
Dividend yield
1.93%
F-score
3/9
Altman Z
4.78
Beneish M
−2.26
Dividend safety
78/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Filings

Johnson & Johnson 8-K filed Jul 17, 2024

Period ended Jul 17, 2024 · Filed · accepted 8:14 AM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov The press release